Formulary Search
You are here : Home > Formulary Search
Search Results : Dementia (Vascular) (Donepezil hydrochloride - Dementia (Vascular))
Show Icon and Status Keys Hide Icon and Status Keys
Icon Key
Status Key
- Oral solution
- Oro-dispersible tablets
- Tablets
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Modified release capsules
- Oral solution
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Oral solution
- Oro-dispersible tablets
- Tablets
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Capsules
- Oral solution
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution for patients who are unable to swallow capsules.
- Patches
PATCHES - ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
SAFETY WARNING - patches are available as DAILY or TWICE WEEKLY but both are described in mg/24 hours. Care required to ensure that the intended patch is prescribed and dispensed.
An MHRA alert has also been issued in response to rivastigmine overdose due to multiple patch application, cutting patches and application of patches to non-recommended sites: https://www.gov.uk/drug-safety-update/rivastigmine-exelon-transdermal-patch-risk-of-medication-errors?UNLID=7961636092025721172155